Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Etoposide 2Disulfides 2Carboplatin 2repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Leucovorin 1IFL protocol 1Fluorouracil 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × BAY 1895344 × 90 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡